Cargando…
Management of left ventricular thrombus: a narrative review
Left ventricular thrombus (LVT) is a serious complication of acute myocardial infarction (MI) and also non-ischemic cardiomyopathies. We performed a narrative literature review, manual-search of reference lists of included articles and relevant reviews. Our literature review indicates that the incid...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039643/ https://www.ncbi.nlm.nih.gov/pubmed/33850917 http://dx.doi.org/10.21037/atm-20-7839 |
_version_ | 1783677638141804544 |
---|---|
author | Cruz Rodriguez, Jose B. Okajima, Kazue Greenberg, Barry H. |
author_facet | Cruz Rodriguez, Jose B. Okajima, Kazue Greenberg, Barry H. |
author_sort | Cruz Rodriguez, Jose B. |
collection | PubMed |
description | Left ventricular thrombus (LVT) is a serious complication of acute myocardial infarction (MI) and also non-ischemic cardiomyopathies. We performed a narrative literature review, manual-search of reference lists of included articles and relevant reviews. Our literature review indicates that the incidence of LVT following acute MI has decreased, probably due to improvement in patient care as a result of better and earlier reperfusion techniques. Predictors of LVT include anterior MI, involvement of left ventricular (LV) apex (regardless of the coronary territory affected), LV akinesis or dyskinesis, reduced LV ejection fraction (LVEF), severe diastolic dysfunction and large infarct size. LVT is associated with increased risk of systemic embolism, stroke, cardiovascular events and death, and there is evidence that anticoagulant therapy for at least 3 months can reduce the risk of these events. Cardiac magnetic resonance (CMR) has the highest diagnostic accuracy for LVT, followed by echocardiography with the use of echocardiographic contrast agents (ECAs). Although current guidelines suggest use of vitamin K antagonist (VKA) for a minimum of 3 to 6 months, there is growing evidence of the benefits of direct acting oral anticoagulants in treatment of LVT. Embolic events appear to occur even after resolution of LVT suggesting that anticoagulant therapy needs to be considered for a longer period in some cases. Recommendations for the use of triple therapy in the presence of the LVT are mostly based on extrapolation from outcome data in patients with atrial fibrillation (AF) and MI. We conclude that the presence of LVT is more likely in patients with anterior ST-segment elevation MI (STEMI) (involving the apex) and reduced ejection fraction (EF). LVT should be considered a marker of increased long-term thrombotic risk that may persist even after thrombus resolution. Ongoing clinical trials are expected to elucidate the best management strategies for patients with LVT. |
format | Online Article Text |
id | pubmed-8039643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-80396432021-04-12 Management of left ventricular thrombus: a narrative review Cruz Rodriguez, Jose B. Okajima, Kazue Greenberg, Barry H. Ann Transl Med Review article on Heart Failure Update and Advances in 2021 Left ventricular thrombus (LVT) is a serious complication of acute myocardial infarction (MI) and also non-ischemic cardiomyopathies. We performed a narrative literature review, manual-search of reference lists of included articles and relevant reviews. Our literature review indicates that the incidence of LVT following acute MI has decreased, probably due to improvement in patient care as a result of better and earlier reperfusion techniques. Predictors of LVT include anterior MI, involvement of left ventricular (LV) apex (regardless of the coronary territory affected), LV akinesis or dyskinesis, reduced LV ejection fraction (LVEF), severe diastolic dysfunction and large infarct size. LVT is associated with increased risk of systemic embolism, stroke, cardiovascular events and death, and there is evidence that anticoagulant therapy for at least 3 months can reduce the risk of these events. Cardiac magnetic resonance (CMR) has the highest diagnostic accuracy for LVT, followed by echocardiography with the use of echocardiographic contrast agents (ECAs). Although current guidelines suggest use of vitamin K antagonist (VKA) for a minimum of 3 to 6 months, there is growing evidence of the benefits of direct acting oral anticoagulants in treatment of LVT. Embolic events appear to occur even after resolution of LVT suggesting that anticoagulant therapy needs to be considered for a longer period in some cases. Recommendations for the use of triple therapy in the presence of the LVT are mostly based on extrapolation from outcome data in patients with atrial fibrillation (AF) and MI. We conclude that the presence of LVT is more likely in patients with anterior ST-segment elevation MI (STEMI) (involving the apex) and reduced ejection fraction (EF). LVT should be considered a marker of increased long-term thrombotic risk that may persist even after thrombus resolution. Ongoing clinical trials are expected to elucidate the best management strategies for patients with LVT. AME Publishing Company 2021-03 /pmc/articles/PMC8039643/ /pubmed/33850917 http://dx.doi.org/10.21037/atm-20-7839 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review article on Heart Failure Update and Advances in 2021 Cruz Rodriguez, Jose B. Okajima, Kazue Greenberg, Barry H. Management of left ventricular thrombus: a narrative review |
title | Management of left ventricular thrombus: a narrative review |
title_full | Management of left ventricular thrombus: a narrative review |
title_fullStr | Management of left ventricular thrombus: a narrative review |
title_full_unstemmed | Management of left ventricular thrombus: a narrative review |
title_short | Management of left ventricular thrombus: a narrative review |
title_sort | management of left ventricular thrombus: a narrative review |
topic | Review article on Heart Failure Update and Advances in 2021 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039643/ https://www.ncbi.nlm.nih.gov/pubmed/33850917 http://dx.doi.org/10.21037/atm-20-7839 |
work_keys_str_mv | AT cruzrodriguezjoseb managementofleftventricularthrombusanarrativereview AT okajimakazue managementofleftventricularthrombusanarrativereview AT greenbergbarryh managementofleftventricularthrombusanarrativereview |